Email this article ACTIVATION OF T. GONDII INFECTION AFTER ALLOGENEIC TRANSPLANTATION OF HEMATOPOIETIC STEM CELLS: DEPENDENCE ON TIME OF TRANSPLANTATION AND SEROLOGICAL STATUS OF THE PATIENTS
- Authors: Chukhlovin A.B.1, Zubarovskaya L.S.2, Bondarenko S.N.2, Eismont Y.A.2, Semenov A.V.3, Vladovskaya M.D.2, Totolian A.3, Afanasyev B.V.2
-
Affiliations:
- R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia 197089, Russian Federation, St. Petersburg, L. Tolstoy str., 6/8, R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University. Phone/fax: +7 (812) 499-70-79
- R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
- St. Petersburg Pasteur Institute, St. Petersburg, Russia
- Issue: Vol 4, No 4 (2014)
- Pages: 381-386
- Section: SHORT COMMUNICATIONS
- URL: https://iimmun.ru/iimm/article/view/250
- DOI: https://doi.org/10.15789/2220-7619-2014-4-381-386
- ID: 250
Cite item
Full Text
Abstract
The article focuses on aspects of T. gondii reactivation/reinfection in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). We have observed 297 patients who received conditioning therapy and allogeneic grafts due to different oncohematological or lymphoproliferative diseases (1 to 60 years old, at a mediane of 19 years). Conditioning regimens were either myeloablative (35%), or non-myeloablative (65%). DNA diagnostics of T. gondii was performed on a regular basis at 0 to 6 months post-HSCT. IgG and IgM antibodies against T. gondii were determined in 78 patients before HSCT, as well as in their donors. T. gondii DNA post-transplant proved to be positive in 13% of blood specimens, 9% of cerebrospinal liquor samples, 11% of bronchoalveolar cell lavages, and in 5% of urine sediments. In adolescent patients (10 to 14 years old), an increased prevalence of T. gondii was found in patients who received myeloablative treatment (p = 0.01). When assessing posttransplant dynamics of T. gondii, we have revealed distinct increase in the pathogen excretion within 1st month after HSCT (p = 0.03). Finally, initial presence of IgG antibodies against T. gondii in the patients was associated with lower incidence of the pathogen reactivation post-transplant.
About the authors
A. B. Chukhlovin
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia 197089, Russian Federation, St. Petersburg, L. Tolstoy str., 6/8,R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University. Phone/fax: +7 (812) 499-70-79
Author for correspondence.
Email: alexei.chukh@mail.ru
PhD (Medicine), Professor, R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationL. S. Zubarovskaya
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Medicine), Professor, Head Department of Pediatric Oncology, Hematology and Transplantology, R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationS. N. Bondarenko
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Medicine), Head Department of Bone Marrow Transplantation in Adolescents, R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationYu. A. Eismont
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Biology), Biologist Department of Clinical Microbiology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationA. V. Semenov
St. Petersburg Pasteur Institute, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Biology), Head Laboratory of Immunology and HIV Virology, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation
Russian FederationM. D. Vladovskaya
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Email: fake@neicon.ru
PhD, Hematologist/Oncologist, R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationAreg A. Totolian
St. Petersburg Pasteur Institute, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Medicine), Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director on Science, St. Petersburg Pasteur Institute, St. Petersburg, Russian Federation
Russian FederationB. V. Afanasyev
R. Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia
Email: fake@neicon.ru
PhD (Medicine), Professor, Director R. Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantology, Pavlov First St. Petersburg State Medical University, St. Petersburg, Russian Federation
Russian FederationReferences
- Инфекционные болезни: национальное руководство / Под ред. Н.Д. Ющука, Ю.Я. Венгерова. 1. М.: ГЭОТАР-Медиа, 2009. 1040 с. [Infectious Diseases: National Manual. Eds. Yushchuk N.D., Vengerov Yu.Ya. Moscow: GEOTAR-Media, 2009, 1040 p.]
- Семенов А.В., Вашукова С.С. Лабораторная диагностика внутриутробных инфекций: методические рекомендации. СПб.: Светлица, 2008. 79 с. [Semenov A.V., Vashukova S.S. Laboratory diagnostics of prenatal infections: guidelines. St. Petersburg: Svetlitsa Publ., 2008. 79 p.]
- Busemann C., Ribback S., Zimmermann K., Sailer V., Kiefer T., Schmidt C.A., Schulz K., Steinmetz I., Dombrowski F., Dölken G., Krüger W.H. Toxoplasmosis after allogeneic stem cell transplantation — a ingle centre experience. Ann. Hematol., 2012, vol. 91, no. 7, pp. 1081–1089.
- Cavattoni I., Ayuk F., Zander A.R., Zabelina T., Bacher A., Cayroglu E., Knospe V., Illies T., Aepfelbacher M., Richard G., Kröger N., Bacher U. Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny. Leuk. Lymphoma, 2010, vol. 51, no. 8, pp. 1530–1535.
- Fricker-Hidalgo H., Bulabois C.E., Brenier-Pinchart M.P., Hamidfar R., Garban F., Brion J.P., Timsit J.F., Cahn J.Y., Pelloux H. Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin. Infect. Dis., 2009, vol. 48, no. 2, pp. e9–e15.
- Janitschke K., Held T., Krüiger D., Schwerdtfeger R., Schlier G., Liesenfeld O. Diagnostic value of tests for Toxoplasma gondiispecific antibodies in patients undergoing bone marrow transplantation. Clin. Lab., 2003, vol. 49, no. 5–6, pp. 239–242.
- Machala L., Malý M., Beran O., Jilich D., Kodym P. Incidence and clinical and immunological characteristics of primary Toxoplasma gondii infection in HIV-infected patients. Int. J. Infect. Dis., 2013, vol. 17, no. 10, pp. e892–е896.
- Martino R., Maertens J., Bretagne S., Rovira M., Deconinck E., Ullmann A.J., Held T., Cordonnier C. Toxoplasmosis after hematopoietic stem cell transplantation. Clin. Infect. Dis., 2000, vol. 31, no. 5, pp. 1188–1195.
- Meers S., Lagrou K., Theunissen K., Dierickx D., Delforge M., Devos T., Janssens A., Meersseman W., Verhoef G., Van Eldere J., Maertens J. Myeloablative conditioning predisposes patients for Toxoplasma gondii reactivation after allogeneic stem cell transplantation. Clin. Infect. Dis., 2010, vol. 50, no. 8, pp. 1127–1134.
- Slavin M.A., Meyers J.D., Remington J.S., Hackman R.C. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant., 1994, vol. 13, no. 5, pp. 549–557.
- Sumi M., Aosai F., Norose K., Takeda W., Kirihara T., Sato K., Fujikawa Y., Shimizu I., Ueki T., Hirosima Y., Ueno M., Ichikawa N., Watanabe M., Kobayashi H. Acute exacerbation of Toxoplasma gondii infection after hematopoietic stem cell transplantation: five case reports among 279 recipients. Int. J. Hematol., 2013, vol. 98, no. 2, pp. 214–222.
- Vidal J.E., Diaz A.V., de Oliveira A.C., Dauar R.F., Colombo F.A., Pereira-Chioccola V.L. Importance of high IgG anti-Toxoplasma gondii titers and PCR detection of T. gondii DNA in peripheral blood samples for the diagnosis of AIDS-related cerebral toxoplasmosis: a case-control study. Braz. J. Infect. Dis., 2011, vol. 15, no. 4, pp. 356–359.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).